H. pylori-Induced Gastric Cancer Model Service

The H. pylori-Induced Gastric Cancer Model Service delivers a biologically faithful in vivo platform in which chronic Helicobacter pylori infection drives the sequential stages of gastric carcinogenesis — from chronic gastritis and atrophy to metaplasia, dysplasia, and gastric adenocarcinoma — mirroring the human Correa cascade in a controlled preclinical setting. Alfa Cytology brings together expertise in bacterial challenge design, gnotobiotic-aware husbandry, longitudinal endoscopic and histopathological staging, and molecular endpoint analysis, offering a turnkey program that carries your H. pylori gastric cancer study from strain selection through a fully documented final report.

Overview of H. pylori-Induced Gastric Cancer Model

Helicobacter pylori, a spiral Gram-negative bacterium that colonizes the human gastric mucosa, is the single most important identified risk factor for gastric cancer and was classified as a Group 1 biological carcinogen by the WHO/IARC in 1994. The H. pylori-induced gastric cancer model translates this epidemiological reality into an experimentally tractable system: susceptible rodents — most notably the Mongolian gerbil, in which adenocarcinoma resembling the human intestinal type was first reproducibly induced by Watanabe and colleagues in 1998 — are orally infected with the bacterium and followed as infection evolves through the histological sequence that defines the Correa cascade: chronic active gastritis, loss of parietal and chief cells (oxyntic atrophy), spasmolytic polypeptide-expressing metaplasia (SPEM), intestinal metaplasia, dysplasia, and ultimately invasive adenocarcinoma.

Fig 1. In vitro characterisation of theRM-1 cell lines edited for mCAIX expression. (Noto, Jennifer M., et al., 2016)

The pathogenic logic of the model rests on the interplay between bacterial virulence and host response. Strains bearing the cag pathogenicity island inject the CagA oncoprotein into gastric epithelial cells through a type IV secretion system, deregulating SHP-2 signaling and triggering IL-8–mediated inflammation, while VacA pore-forming toxin variants (s1/i1/m1 types) intensify epithelial injury. Sustained inflammation, oxidative stress, and altered gastric microbiota progressively remodel the mucosa, expanding metaplastic lineages that serve as substrates for neoplastic transformation. Because wild-type mice typically arrest at gastritis and metaplasia whereas gerbils and hypergastrinemic INS-GAS transgenic mice progress to carcinoma, the platform can be deliberately tuned — by host genetics, bacterial strain choice, co-carcinogen exposure, or diet — to interrogate virtually every stage of Helicobacter-driven tumorigenesis in vivo.

Principles of H. pylori-Induced Gastric Cancer Model Construction

Successful construction of this model hinges on three interacting variables: the bacterium, the host, and the environment. The bacterium must both colonize the gastric niche and express virulence determinants capable of sustaining chronic inflammation; the host must be genetically permissive to lesion progression; and environmental inputs such as the gastric microbiota, dietary salt, and chemical co-carcinogens set the tempo of disease. In the canonical gerbil protocol, repeated high-dose oral gavage establishes robust colonization, and the ensuing decades-compressed Correa cascade unfolds over roughly a year. In mice, where most H. pylori strains colonize weakly or fail to provoke carcinoma, mouse-adapted strains and transgenic sensitization close the gap between inflammation and cancer.

Our Services

Alfa Cytology operationalizes this demanding model with disciplined microbiology and pathology workflows: authenticated H. pylori strains are expanded under quality-controlled conditions and titered before every gavage series, animals are housed and fasted according to validated challenge SOPs, and infection is confirmed, staged, and archived at each interval — with interim datasets shared throughout the study so your program never loses sight of progressing lesions.

Workflow of H. pylori-Induced Gastric Cancer Model Construction

Building the H. pylori gastric cancer model is a staged program that couples bacterial challenge with months of monitored lesion development. The workflow below maps each phase from study planning to final histopathological and molecular readout.

1. Study design and model selection: The scientific question determines the platform: Mongolian gerbils for the full carcinoma endpoint, wild-type C57BL/6 mice for gastritis-to-metaplasia studies, or INS-GAS mice for accelerated adenocarcinoma — with group sizes, co-carcinogen arms, and sampling intervals fixed in advance.
2. Bacterial strain preparation and quality control: The selected H. pylori strain (e.g., SS1 or PMSS1 for mouse studies) is revived from authenticated stocks, expanded on blood-based media under microaerobic conditions, and verified for viability, identity, and expected CFU counts prior to challenge.
3. Animal preparation and fasting: Rodents are acclimatized, randomized into study groups, and fasted for 8–12 hours before gavage to reduce gastric contents and improve bacterial survival during inoculation.
4. Oral bacterial challenge: Each animal receives the bacterial suspension by oral gavage — classically 0.5 mL at approximately 1 × 10⁹ CFU per dose, repeated once after 24–48 hours — with sham-infected controls gavaged with sterile broth.
5. Colonization confirmation: At predefined checkpoints, gastric tissue is sampled and assessed by rapid urease testing, culture, and PCR/qPCR to verify stable infection and quantify colonization density across groups.
6. Longitudinal disease monitoring: Animals are tracked for body weight and clinical status, while cohort subsets undergo scheduled gastroscopic examination or biopsy to grade lesion severity and harvest tissue for in vitro analyses without terminating the cohort.
7. Endpoint histopathology and molecular analysis: At study termination, stomachs are fixed, sectioned, and scored by the updated Sydney system for inflammation, atrophy, metaplasia, and dysplasia; SPEM/intestinal markers, cytokine expression, and H. pylori burden are integrated into the final dataset and report.

Fig 2. H. pylori-Induced Gastric Cancer Model Construction Workflow.

Case Study-H. pylori-Induced Gastric Cancer Model Development

Alfa Cytology has executed H. pylori-induced gastric cancer studies for preclinical programs spanning chemoprevention, eradication-based intervention, and host–pathogen mechanism research. Engagements of this type typically cover authenticated strain expansion, standardized oral challenge, confirmed colonization across cohorts, interval histological staging along the Correa cascade, and terminal molecular characterization — yielding lesion-incidence, severity-scoring, and treatment-response datasets that clients use for candidate prioritization. Illustrative study data and timelines are available upon request.

Why Choose Alfa Cytology?

A Helicobacter cancer study succeeds or fails on microbiological rigor and histopathological judgment. Alfa Cytology unites both under one quality framework, so the strain you specified is the strain that gavages your animals — and every lesion is scored by eyes trained on the Correa cascade.

• Authenticated, quality-controlled H. pylori strain banks with viability and titer verification before each challenge.
• Validated challenge SOPs across gerbil, wild-type, and INS-GAS platforms with confirmed colonization rates.
• Systematic Sydney-system histopathological staging with dedicated SPEM/intestinal metaplasia marker panels.
• Flexible study architectures supporting eradication, chemoprevention, and co-carcinogen acceleration arms.
• Longitudinal monitoring options, including serial gastroscopy and non-terminal biopsy cohorts.
• Exclusively preclinical operations — your research-stage program receives our full, undivided focus.
• Transparent interim reporting that keeps stakeholders informed from first gavage to final dataset.

Contact Us

If your program requires a rigorously controlled in vivo system for Helicobacter-driven gastric carcinogenesis, reach out to us to scope the right platform — gerbil, wild-type mouse, or INS-GAS — around your mechanistic or therapeutic objectives. Contact Alfa Cytology today, and our team will respond with a tailored study proposal and timeline.

For research use only. Not intended for any clinical use.